SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Merck & Co Inc

Merck is trending as investors focus on the potential for strategic acquisitions to bolster its oncology pipeline ahead of key patent expirations. Community sentiment is heavily centered on rumors of a bidding war for various biotech targets as the pharma giant seeks to secure the next generation of cancer treatments.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is attracting significant attention as investors track the imminent release of phase 3 IZAR-1 trial results in psoriatic arthritis, with the community actively speculating on a potential buyout given the company's strong cash position and best-in-class immunology pipeline. Recent institutional interest through a large equity raise has set a new floor, while sentiment remains intensely focused on whether the upcoming data will trigger a major bidding war from big pharma.

Zcash is a privacy-focused cryptocurrency that uses trustless zero-knowledge proofs to enable fully encrypted transactions while maintaining blockchain transparency and security. It was the first cryptocurrency to implement zero-knowledge encryption for private peer-to-peer payments, addressing the fundamental privacy gap in traditional cryptocurrencies that expose transaction details publicly.   With a fixed supply of 21 million ZEC and a halving schedule similar to Bitcoin, Zcash allows users to prove transactions are valid without revealing sensitive information like wallet balances, transaction amounts, or participant identities, making it suitable for everyday payments, long-term savings, and cross-border money transfers where financial confidentiality matters.  The protocol operates on its own blockchain currently using Proof-of-Work consensus, though it's evolving toward Proof-of-Stake through the planned "Crosslink" upgrade to enhance security, scalability, and energy efficiency. Zcash employs trustless zero-knowledge proofs (Halo) within its Orchard shielded pool to verify transactions without revealing sender, receiver, or amount information.   Users can choose between transparent public transactions and shielded private transactions through Unified Addresses, which work with both types. The network is faster and cheaper than Bitcoin, with new blocks mined every 75 seconds and transaction fees typically just a fraction of a cent. Privacy adoption has surged in 2025, with over 30% of total ZEC supply now held in fully shielded pools.  Zcash was created by a group of scientists in 2013 who initially proposed Zerocoin as a privacy extension to Bitcoin before building a standalone protocol. The ecosystem operates with a self-funded development model where block rewards support independent teams through the Zcash Community Grants Committee and a new Coinholder-Controlled Fund.

Zcash

Zcash is facing intense volatility and a significant price correction following the discovery of a critical vulnerability in its Orchard pool that could have potentially enabled unauthorized token creation. While the team has released a patch, the community remains divided and deeply concerned over the inability to definitively audit the supply to confirm if any tokens were minted while the flaw was active.

C3.ai, Inc. engages in the provision of enterprise artificial intelligence software for digital transformation. It delivers the C3 AI suite for developing, deploying, and operating large-scale AI, predictive analytics, and Internet of Things applications in addition to a portfolio of turn-key AI applications. It operates through the following geographical segments: North America, Europe, The Middle East, and Africa, Asia Pacific, and Rest of World. The company was founded by Thomas M. Siebel, Patricia A. House and Stephen Maurice Ward, Jr. on January 8, 2009 and is headquartered in Redwood City, CA.

C3.ai Inc - Ordinary Shares - Class A

C3.ai Inc

C3.ai is currently trending as investors weigh aggressive institutional accumulation and high short interest against concerns regarding revenue growth and a complex sales turnaround. The community is heavily focused on the company's recent leadership shifts and the potential for a short squeeze, while debates persist over whether its enterprise software strategy can compete effectively in the broader AI sector.

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Johnson & Johnson

Johnson & Johnson is currently garnering attention as investors rotate into defensive, high-quality healthcare names amid broader market volatility. The community remains focused on the company's strong dividend track record, recent positive clinical trial updates for its oncology pipeline, and active discussions surrounding potential M&A activity within the pharmaceutical sector.

Mastercard, Inc. is a technology company, which engages in the provision of payment solutions for the development and implementation of credit, debit, prepaid, commercial, and payment programs through its brands including Mastercard, Maestro, and Cirrus. It also offers cyber and intelligence solutions. The company was founded in November 1966 and is headquartered in Purchase, NY.

Mastercard Incorporated - Ordinary Shares - Class A

Mastercard Inc

Mastercard is drawing investor attention as it navigates a volatile market environment shaped by potential regulatory scrutiny over credit card interest rate caps and broader AI-driven fintech disruption. While community members remain divided on whether these pressures represent a long-term threat to the company's payment rail dominance, many are actively monitoring the stock as a potential value opportunity given its consistent cash flow and high-quality fundamentals compared to high-beta growth plays.

ASML Holding NV engages in the development, production, marketing, sales, upgrading and servicing of advanced semiconductor equipment systems. It includes lithography, metrology and inspection systems. The company was founded on April 1, 1984 and is headquartered in Veldhoven, the Netherlands.

ASML Holding NV - New York Shares

ASML Holding NV

ASML remains a central focus as the semiconductor industry grapples with supply chain bottlenecks and rising capex from major manufacturers, reinforcing its status as a critical lithography monopoly. Community sentiment is currently driven by a mix of long-term conviction in the AI infrastructure buildout and short-term volatility following analyst target upgrades and debates over the adoption curve of its next-generation lithography equipment.

Avalanche is a high throughput smart contract blockchain&nbsp;platform. Validators secure the network through a proof-of-stake consensus protocol. It is said to be fast, low cost, and environmental friendly.

Avalanche

Avalanche (AVAX) is experiencing significant downward pressure, fueling intense community debate over whether current price levels represent a deep-value buying opportunity or a structural decline. Investors are polarized, with some highlighting strong enterprise partnerships and RWA (Real World Asset) integration as signs of long-term potential, while others are frustrated by consistent underperformance and are comparing the token's trajectory to failed or manipulated projects.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

The community is currently fixated on rumors regarding the health and status of high-profile political figures, with intense debate and speculative accusations dominating the discourse. This volatility is further fueled by ongoing geopolitical tensions and broad distrust in the current political climate.

Hedera is a decentralized public network where developers can build secure, fair applications with near real-time consensus. The platform is owned and governed by a council of global innovators including Avery Dennison, Boeing, Deutsche Telekom, DLA Piper, FIS (WorldPay), Google, IBM, LG Electronics, Magalu, Nomura, Swirlds, Tata Communications, University College London (UCL), Wipro, and Zain Group.   The Hedera Consensus Service (HCS) acts as a trust layer for any application or permissioned network and allows for the creation of an immutable and verifiable log of messages. Application messages are submitted to the Hedera network for consensus, given a trusted timestamp, and fairly ordered. Use HCS to track assets across a supply chain, create auditable logs of events in an advertising platform, or even use it as a decentralized ordering service.

Hedera Hashgraph

Hedera Hashgraph is currently facing significant community debate as investors weigh concerns over tokenomics and corporate governance against its long-term potential for institutional utility. While some holders are frustrated by recent price volatility and slow adoption, others are actively accumulating tokens, viewing the current market sentiment as an opportunity to build positions in what they consider a foundational technology for the future of finance.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

FTRE or ARGX: Which Is the Better Value Stock Right Now?

FTRE vs. ARGX: Which Stock Is the Better Value Option?

TGTX Rises on Positive Phase I Data for Subcutaneous Briumvi in MG

TG Therapeutics gains after positive phase I data for subcutaneous Briumvi in myasthenia gravis or MG, while a phase II study in MG gets underway.

ARGX Shares Gain Nearly 9% in a Month: Here's What You Need to Know

argenx stock rises nearly 9% in a month after the FDA expands Vyvgart's gMG label, opening treatment to  adult patients regardless of antibody status.

SRPT vs. ARGX: Which Stock Is the Better Value Option?

Argenx (ARGX) Soars 5.8%: Is Further Upside Left in the Stock?

Argenx (ARGX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

The Biology Came First.

MindWalk Holdings Corp. (NASDAQ: HYFT) today released a systematic report identifying over 20 discovery-originated drug candidates with documented origins in antibody discovery work performed at...

Halozyme's Q1 Earnings & Revenues Beat Estimates, Stock Up

HALO beats Q1 earnings estimates as royalty revenues from partner drugs and strong product sales lift revenues by 42% year over year.

HRMY or ARGX: Which Is the Better Value Stock Right Now?

HRMY vs. ARGX: Which Stock Is the Better Value Option?

Jennison Associates LLC Reduces Stock Position in argenex SE $ARGX

Jennison Associates LLC cut its stake in argenex SE (NASDAQ:ARGX - Free Report) by 4.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange...

argenex (ARGX) to Release Earnings on Thursday

argenex (NASDAQ:ARGX) will be releasing its Q1 2026 earnings before the market opens on Thursday, May 7. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-7-argenx-se-stock...

argenx SE is a global immunology company, which engages in improving the lives of people suffering from severe autoimmune diseases. It operates through the following geographical segments: United States, Japan, EMEA, and China. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren in 2008 and is headquartered in Amsterdam, the Netherlands.

Argen X SE - ADR

DNTH Stock Soars After Early ‘Go’ Decision For Drug In Autoimmune Disorder Program, Boosting Wall Street Optimism For Potential Launch

Equity

Bearish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$877.62
Prev Close	$909.49
Open	$904.79
Dividend Yield	0.00%
50-Day Moving Average	$848.63
Beta	0.64
Avg. Volume	405,178.83
PE Ratio	41.60

52-Week High	$953.58
52-Week Low	$554.59
Market Capitalization	$54.58B
EPS (Annual)	$21.14
Price to Book	7.42
Revenue Per Employee	$2.24M

Feed

News

Sentiment

Earnings

Fundamentals

Info

ARGXArgenx

Latest ARGX News